Testing a tool to measure liver inflammation in NAFLD
Part of Digestive system clinical trials.
This trial studies a device called LivQ-box to see if it can accurately measure liver inflammation in people with nonalcoholic fatty liver disease (NAFLD). It compares the device's results to a liver biopsy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with nonalcoholic fatty liver disease (NAFLD).
- You are at least 18 years old.
- You do not have other liver diseases, such as hepatitis, drug-induced liver injury, or autoimmune liver disease.
- You are willing to have a special liver exam (iLivTouch) within 2 weeks of a standard liver biopsy.
- You do not drink more than 1 drink per day (women) or 2 drinks per day (men).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a new scoring method can help doctors identify liver inflammation in patients who have both type 2 diabetes and a fatty liver. The goal is to find an easier, safer way to assess liver health without invasive procedures.
This trial studies whether LivPhcD capsules can improve fatty liver disease and checks for side effects. It may help people with non-alcohol-related fatty liver disease who meet specific liver-scanning and lab results.
This study tests a new device called LiverScope® that scans your liver to detect fatty liver disease (MASLD). The scan uses special imaging technology and may help doctors diagnose liver disease more quickly and accurately.
This study compares two non-invasive approaches to diagnose advanced liver scarring in people with non-alcohol-related fatty liver disease (NAFLD). It may help confirm which test strategy finds advanced scarring without needing a biopsy for everyone.
This trial tests a new wearable patch that uses ultrasound to measure liver stiffness, which can help diagnose scarring. It may be an option if you already need or recently had a FibroScan for chronic liver disease.
This trial tests a new medication for people with fatty liver disease. It will see if the drug can reduce liver fat and improve liver health over several doses.
Hear when a new Liver Inflammation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.